CellSource

Name

CellSource

Website

https://cellsource.co.jp

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Health Services (8000)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Therapy Developers (Autologous) (HLAAABAA)

Keywords

• Regenerative medicine services
• Electronic medical records
• Medical rehabilitation services
• Healthcare digital transformation
• Medical institution support

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Core offering

CellSource operates a regenerative medicine business that supports medical institutions in Japan, including an electronic medical record service (Medibase) acquired in September 2024 to advance digital transformation in healthcare. The company is also partnering with C-FORTE Inc. to build an integrated medical delivery model combining regenerative medicine and rehabilitation, with nationwide deployment planned to begin in April 2026. Together, these offerings address gaps in collaboration between regenerative medicine and rehabilitation, know-how gaps in self-funded medical care, and digital transformation challenges in the medical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Medibase Electronic medical record service providing digital record management and digital transformation tooling for medical institutions in Japan. Acquired via the Medibase Inc. share transfer to Cellsource Inc.
• CellSource Regenerative Medicine Services

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• C-FORTE Inc.coreStrategic or Co-development Partner · 1 April 2026Cellsource Inc. and C-FORTE Inc. announced a business partnership to build a new medical delivery model integrating regenerative medicine and rehabilitation in Japan. The partnership addresses challenges including the lack of collaboration between regenerative medicine and rehabilitation, know-how gaps for self-funded medical care, and insufficient patient contact points. The two companies will organize physical therapists, establish certification systems, and support medical institutions in deploying combined treatment protocols, with gradual nationwide deployment starting in April 2026.
• Medibase Inc.coreStrategic or Co-development Partner · 12 September 2024Medibase Inc. transferred shares to Cellsource Inc. and joined the Cellsource Group as of September 12, 2024. The merger aims to leverage combined expertise to expand into new medical areas and enhance digital transformation efforts in the medical industry. Medibase developed the electronic medical record service Medibase.

Broad incumbents

• M3, Inc. Large Japanese medical platform providing physician-facing digital services including MR-kun, medical DX, and clinical decision support. M3 is a broad incumbent in the Japanese medical DX space where CellSource's Medibase EMR subsidiary competes, though M3 is much larger and broader in scope.
• Rohto Pharmaceutical Co., Ltd. Diversified Japanese healthcare company with regenerative medicine and cell therapy subsidiaries. Rohto is a broader incumbent with regenerative medicine activities and a Japan-listed public profile comparable to CellSource's structure.
• PHC Holdings Corporation: Japan-listed global medical device and healthcare IT company (formerly Panasonic Healthcare) providing medical equipment, diagnostics, and digital health solutions. PHC is a broad incumbent in medical technology whose digital health portfolio overlaps with CellSource's medical DX positioning.
• Medical Data Vision Co., Ltd. Japanese healthcare data and medical DX company that aggregates hospital data and provides analytics and electronic medical record-adjacent services. Comparable to CellSource's Medibase subsidiary on the hospital-side medical DX and EMR data side.

Regional players

• EPS Holdings, Inc. Japan-based CRO and healthcare services holding company with a similar roll-up strategy of medical and clinical service businesses. Comparable to CellSource's holding-company consolidation approach in the Japanese healthcare services market.

Direct peers

• Healios K.K. Japanese regenerative medicine company developing stem cell therapies (e.g., HLCM051 for acute respiratory distress, stem cell therapy for knee osteoarthritis). Healios is a direct competitor in autologous/allogeneic stem cell-based regenerative therapies and a near-term benchmark for Japanese regenerative medicine capital markets.
• Japan Tissue Engineering (J-TEC): Subsidiary of Terumo that develops and commercializes regenerative medicine products including autologous cell therapies for cartilage and skin. J-TEC is the most direct Japanese comparison to CellSource's regenerative medicine franchise, with overlapping autologous cell therapy focus and hospital-channel distribution.
• MEDINET Co., Ltd. Japanese cell therapy services company providing cell processing and contract manufacturing for regenerative medicine developers. MEDINET is comparable to CellSource on the cell therapy clinical services and manufacturing side of the regenerative medicine value chain.

Emerging players

• Helix Japan Co., Ltd. Japanese regenerative medicine CDMO/CMO providing cell processing and manufacturing services. Helix Japan is comparable as a specialized cell therapy manufacturing and services provider in the same Japanese regenerative medicine ecosystem.
• Tella, Inc. Japan-listed regenerative medicine company developing cell therapies, including a DDS-001 stem cell product for dental applications. Tella is a smaller emerging Japanese peer in stem cell-based regenerative therapies with comparable clinical-stage positioning.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellSource